Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 4,153 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,153 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $35.30, for a total value of $146,600.90. Following the completion of the transaction, the insider now owns 161,497 shares in the company, valued at approximately $5,700,844.10. This represents a 2.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total value of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $70,055.70.

Hims & Hers Health Stock Down 4.4 %

NYSE:HIMS opened at $40.36 on Friday. The firm has a market capitalization of $8.82 billion, a price-to-earnings ratio of 91.72 and a beta of 1.35. Hims & Hers Health, Inc. has a twelve month low of $9.14 and a twelve month high of $44.43. The stock’s 50 day moving average price is $30.02 and its two-hundred day moving average price is $23.12.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same period in the previous year, the company posted ($0.04) EPS. The firm’s revenue for the quarter was up 77.1% compared to the same quarter last year. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

HIMS has been the topic of a number of recent analyst reports. Piper Sandler raised their target price on Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Monday, January 6th. Needham & Company LLC raised their target price on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, January 6th. TD Cowen reiterated a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Morgan Stanley assumed coverage on Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $25.13.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Main Management ETF Advisors LLC bought a new stake in shares of Hims & Hers Health in the third quarter valued at about $672,000. Robeco Institutional Asset Management B.V. bought a new position in shares of Hims & Hers Health in the third quarter worth $604,000. Carnegie Investment Counsel bought a new position in shares of Hims & Hers Health in the third quarter worth $5,531,000. Royce & Associates LP grew its position in Hims & Hers Health by 17.0% in the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after acquiring an additional 49,500 shares during the last quarter. Finally, Versor Investments LP bought a new position in Hims & Hers Health in the third quarter valued at about $634,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.